AI confidence 70% · prior close shown (market closed)
Investment Snapshot
Why it matters
First Tracks Biotherapeutics, Inc. execution reads as mixed on proprietary earnings and initiative evidence.
Why it matters: First Tracks Biotherapeutics Launch (Q2 FY2026).
3 signals not yet derived from pipeline evidence
Key signals
What it means for the thesis — synthesis, not a raw event feed.
- First Tracks Biotherapeutics Launch (Q2 FY2026)
- Spin-off from AnaptysBio (Q2 FY2026)
Pipeline evidence · 0d ago
TRAX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on TRAX.
Free accounts see more of this; Premium sees all of it.
Latest Intelligence
Updated
What happened recently for First Tracks Biotherapeutics, Inc. (TRAX) — events, not interpretation.
- Event
- Last session September 29, 2026 at $35.98.
- Source
- Market data
Research & analysis only — not investment advice.
Building company intelligence…
First Tracks Biotherapeutics, Inc. (TRAX)
Investment Snapshot above is the primary AlphaOS analysis for First Tracks Biotherapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Key facts
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market cap:
- $1.29B
Research & analysis only — not investment advice. Price, charts, and filings are above.
Connected intelligence
Follow First Tracks Biotherapeutics, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Related & Connected
Same industry
Related stock research
Connected companies and research pages from the AlphaOS knowledge graph.
- HUMANA INC (HUM)Investment Snapshot & knowledge graph →
- CANADIAN PACIFIC KANSAS CITY LTD/CN (CP)Investment Snapshot & knowledge graph →
- CAMECO CORP (CCJ)Investment Snapshot & knowledge graph →
- UNION PACIFIC CORP (UNP)Investment Snapshot & knowledge graph →
- CARDINAL HEALTH INC (CAH)Investment Snapshot & knowledge graph →
- PACCAR INC (PCAR)Investment Snapshot & knowledge graph →